Cassidy F P, Zajko A B, Bron K M, Reilly J J, Peitzman A B, Steed D L
AJR Am J Roentgenol. 1987 Oct;149(4):671-5. doi: 10.2214/ajr.149.4.671.
During a 5-year period, 416 long-term double-lumen central venous catheters were inserted into 288 patients. In these patients, 106 catheter venograms and nine upper extremity venograms were performed. All studies were reviewed retrospectively to determine the nature and prevalence of noninfectious catheter-related complications, to evaluate the efficacy and safety of streptokinase therapy, and to determine if catheter venography should be performed before streptokinase therapy is started. Noninfectious complications occurred in 66 (23%) patients. Complications that resulted in catheter malfunction included deposition of fibrin around the catheter tip (formation of a fibrin sheath) in 44 (57%) instances, a constricting suture in six, abutment of the catheter tip against the venous wall in eight, catheter leak in two, and migration of the catheter completely out of the vein in three. Venous thrombosis developed in 11 patients. Treatment with low doses of streptokinase successfully relieved catheter obstruction due to a fibrin sheath in 27 (87%) of 31 instances. No bleeding complications occurred. Five patients had malpositioned catheters in the azygous, axillary, or internal jugular veins. By use of a deflector wire or snare inserted via the femoral vein, all five were relocated successfully into the superior vena cava. Recognition of noninfectious complications associated with use of long-term catheters is important for institution of appropriate therapy, which in many instances obviates removal of the catheter. Formation of a fibrin sheath in only 57% of cases of catheter malfunction provides an argument for performing catheter venography before streptokinase therapy is started. Low-dose streptokinase therapy for long-term central venous catheters occluded by a fibrin sheath is safe and efficacious.
在5年期间,为288例患者插入了416根长期双腔中心静脉导管。对这些患者进行了106次导管静脉造影和9次上肢静脉造影。所有研究均进行回顾性分析,以确定非感染性导管相关并发症的性质和发生率,评估链激酶治疗的疗效和安全性,并确定在开始链激酶治疗前是否应进行导管静脉造影。66例(23%)患者发生非感染性并发症。导致导管功能障碍的并发症包括44例(57%)导管尖端周围纤维蛋白沉积(形成纤维蛋白鞘)、6例缝线收紧、8例导管尖端抵住静脉壁、2例导管渗漏以及3例导管完全移出静脉。11例患者发生静脉血栓形成。低剂量链激酶治疗成功缓解了31例中27例(87%)因纤维蛋白鞘导致的导管阻塞。未发生出血并发症。5例患者的导管在奇静脉、腋静脉或颈内静脉位置不当。通过经股静脉插入的转向导丝或圈套器,所有5例均成功重新定位至上腔静脉。认识到与长期导管使用相关的非感染性并发症对于制定适当的治疗措施很重要,在许多情况下可避免拔除导管。仅57%的导管功能障碍病例形成纤维蛋白鞘,这为在开始链激酶治疗前进行导管静脉造影提供了依据。低剂量链激酶治疗纤维蛋白鞘阻塞的长期中心静脉导管安全有效。